← Back to Home

Dren Bio raises $350 million to advance CD94 antibody for rare blood cancers

The funding will support late-stage trials, a marketing application and commercialization preparations for dibotatug. However, the financing announcement disclosed no specific efficacy data, and further clinical evidence is needed to establish how much patients may benefit.

By SURL BioNews

For patients with rare blood cancers, whether a drug candidate can complete clinical trials and reach clinical practice depends not only on efficacy but also on sufficient funding. On October 29, Dren Bio announced the completion of a $350 million private financing to advance its CD94-targeting antibody dibotatug into late-stage development and a marketing application, primarily focusing on cytotoxic T-cell lymphoma and large granular lymphocytic leukemia.

The oversubscribed financing was co-led by Juvia Group and Lightspeed Venture Partners, with participation from OrbiMed, Cormorant Asset Management and General Catalyst, among others. According to information from S&P Capital IQ published by MarketScreener, the financing involved the issuance of convertible preferred stock. Juvia’s Sujal Shah and Lightspeed’s Shelley Chu also joined the board of directors.

Dibotatug, also known as DR-01, is a monoclonal antibody targeting CD94. According to pharmaphorum, CD94 is present on the surface of pathogenic cytotoxic T lymphocytes, natural killer cells and some tumor cells. The therapy is designed to recognize and eliminate these cells. The company hopes to preserve broader immune function while targeting pathogenic cells, but this selectivity and its clinical significance still require validation in trials.

The two main indications impose different disease burdens. The company’s announcement describes cytotoxic T-cell lymphoma as aggressive and associated with a poor prognosis. Large granular lymphocytic leukemia is a chronic hematologic malignancy that can cause severe neutropenia, anemia and even transfusion dependence. A key question in development is whether eliminating the relevant cells can translate into sustained and meaningful improvement in disease.

The clinical progress that can currently be confirmed is that more than 300 patients have received dibotatug in its Phase 1/2 study. The company reported favorable overall and complete responses, as well as safety and tolerability, in relapsed or refractory disease. However, the announcement did not provide specific response rates, duration of response or adverse event rates. The number of patients who received treatment is also not equivalent to the number evaluable for efficacy, so the announcement alone cannot establish the magnitude of efficacy or allow comparisons with existing treatments.

The funding will also be used beyond these two blood cancers. In addition to supporting late-stage development, regulatory submissions and the planned commercial launch of dibotatug, the company will explore other indications and advance its broader research and development pipeline. According to pharmaphorum, this includes DR-0202, a bispecific antibody program that recruits myeloid cells to fight cancer cells, a different approach from dibotatug’s CD94-targeting strategy.

The financing gives Dren Bio more resources to bridge clinical trials and commercialization preparations, but a commercial launch remains a planned next step. The meaningful measures of progress will be the design of trials supporting a marketing application and the full disclosure of response durability and safety data. That evidence will show whether the development commitments supported by this funding can become a new option available to patients.

References

  1. BioSpace
  2. Dren Bio
  3. S&P Capital IQ via MarketScreener
  4. pharmaphorum